Blood test can predict kidney disease 5 years before damage starts
Stephen FellerCHICAGO, Nov. 6 (UPI) -- Testing blood for soluble urokinase-type plasminogen activator receptor can predict risk for developing chronic kidney disease 5 years before it causes harm. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 6, 2015 Category: Consumer Health News Source Type: news

Early warning found for chronic kidney disease
A simple blood test for the suPAR protein can predict a person's chances of developing chronic kidney disease five years before symptoms emerge, thus doing for kidney disease what cholesterol has done for cardiovascular disease, new research shows. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 5, 2015 Category: Science Source Type: news

Early Warning Sign for Kidney Disease Identified in Study
Researchers say blood test can predict risk up to five years before damage begins Source: HealthDay Related MedlinePlus Pages: Chronic Kidney Disease, Laboratory Tests (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 5, 2015 Category: Consumer Health News Source Type: news

When Initiating Dialysis, Can eGFR Stand Alone?When Initiating Dialysis, Can eGFR Stand Alone?
New Japanese guidelines raise questions about whether creatinine levels are sufficient to determine the need for dialysis in chronic kidney disease, says Dr Jeffrey Berns. Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 28, 2015 Category: Consumer Health News Tags: Nephrology Commentary Source Type: news

NICE approves new drug for chronic kidney disease
For the first time, a treatment will be available on the NHS in England and Wales that can delay the development of autosomal dominant polycystic kidney disease (ADPKD). (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - October 28, 2015 Category: Nursing Source Type: news

Chronic Heartburn Drugs Tied to Higher Risk of Kidney Disease
But studies weren't designed to prove proton pump inhibitors are responsible for the increase Source: HealthDay Related MedlinePlus Pages: Chronic Kidney Disease, Heartburn (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 27, 2015 Category: Consumer Health News Source Type: news

Revascularization in Patients With Multivessel CAD and CKDRevascularization in Patients With Multivessel CAD and CKD
Find out more about the treatment paradox for patients with chronic kidney disease who need coronary revascularization. Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

DR ELLIE CANNON: I'm losing sleep over back ache  
The Mail on Sunday's GP answers readers' questions on ankylosing spondylitis and chronic kidney disease, and praises Oprah Winfrey for her decision to use WeightWatchers. (Source: the Mail online | Health)
Source: the Mail online | Health - October 26, 2015 Category: Consumer Health News Source Type: news

Kidney Patients without Online Access Face Additional Burden
Blacks and the poor are often 'left behind,' researcher says Source: HealthDay Related MedlinePlus Pages: Chronic Kidney Disease, Health Disparities (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 22, 2015 Category: Consumer Health News Source Type: news

Peninsula biotech eyes drug launch after winning FDA approval
Relypsa Inc. won its first drug approval Wednesday as the Food and Drug Administration approved its treatment for potentially fatal levels of potassium in chronic kidney disease patients. The drug, for which the Redwood City company (NASDAQ: RLYP) hadn't announced a price as of late Wednesday afternoon, will carry a "boxed warning" because it could cause other oral drugs to be less effective. A Relypsa spokesman said the company would discuss pricing on a conference call Thursday morning. Pricing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 22, 2015 Category: Biotechnology Authors: Ron Leuty Source Type: news

Investigators create complex kidney structures from human stem cells derived from adults
A highly efficient method has been developed for making kidney structures from stem cells that are derived from skin taken from patients. The kidney structures formed could be used to study abnormalities of kidney development, chronic kidney disease, the effects of toxic drugs, and be incorporated into bioengineered devices to treat patients with acute and chronic kidney injury, say scientists. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 17, 2015 Category: Science Source Type: news

A Mysterious Epidemic Plaguing Central America May Be Linked To Climate Change
A mysterious disease has been sweeping through the sugar cane fields of Central America, with more than 20,000 laborers dying from it over the past decade. As of 2012, it had killed the husbands of more than 100 women of the 250 families living on one island in Nicaragua, giving rise to the grim nickname “Island of the Widows.” “Chronic Kidney Disease of nontraditional causes,” as researchers have called the condition, attacks the kidneys and prevents the body from eliminating waste and excess fluid. As the name suggests, no one really knows what causes it. A new report, however, shows&nbs...
Source: Science - The Huffington Post - October 16, 2015 Category: Science Source Type: news

Investigators create complex kidney structures from human stem cells derived from adults
(Brigham and Women's Hospital) Investigators at Brigham and Women's Hospital and the Harvard Stem Cell Institute have established a highly efficient method for making kidney structures from stem cells that are derived from skin taken from patients. The kidney structures formed could be used to study abnormalities of kidney development, chronic kidney disease, the effects of toxic drugs, and be incorporated into bioengineered devices to treat patients with acute and chronic kidney injury. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2015 Category: Global & Universal Source Type: news

CKD Guideline Implementation in Primary CareCKD Guideline Implementation in Primary Care
Are primary care physicians appropriately following guidelines to identify and manage early stage chronic kidney disease? What are the key barriers to guideline implementation? Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2015 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Osprey rises on FDA 510(k) for DyeVert
Osprey Medical (ASX:OSP) said it received FDA 510(k) clearance for its DyeVert contrast modulation system, sending shares of the company to a nearly 2-month high. The DyeVert system automates contrast modulation during manual dye injections, self adjusting for catheter and contrast types without requiring user adjustments, Osprey said. “With FDA Clearance of our DyeVert System, we will now gain real-world physician use to gauge market acceptance of the product’s additional automation and ease-of-use benefits,” CEO Mike McCormick said in a press release. A trial of the DyeVert system is underway in Austral...
Source: Mass Device - October 12, 2015 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Catheters Food & Drug Administration (FDA) Regulatory/Compliance Vascular Osprey Medical Source Type: news

Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Language: English Contact: ...
Source: Merck.com - Research and Development News - October 5, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

5 Things Your Pet Insurance Policy Should Cover
Currently, there are over a dozen companies in the U.S. and Canada offering pet insurance, and if you've tried sorting out the differences between them, like many pet owners, you probably wound up more confused than when you started. As is the case with insurance of any kind, pet health care coverage is a wonderful thing to have if you need it -- and providing there are no big surprises when you submit a claim for reimbursement. Here's the scenario you want to avoid: You faithfully pay your monthly premium for years and enjoy peace of mind knowing your pet's health care will be paid for in the event of an expensive illne...
Source: Healthy Living - The Huffington Post - September 30, 2015 Category: Consumer Health News Source Type: news

The Epigenetics of Acute and Chronic Kidney DiseaseThe Epigenetics of Acute and Chronic Kidney Disease
This new article discusses the emerging field of epigenetic therapy, and the evolving role that it could play in the future treatment of renal disease. Kidney International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2015 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

How Low Can You Go?
Though Chubby Checker recorded these lyrics to Limbo Rock in 1962, the popular catchphrase still holds true today--especially when it comes to your blood pressure. Ever since 1967, we've been aiming to go low. That is the year the first Veterans Administration Cooperative Trial was published, which confirmed that treatment of patients with high blood pressure resulted in fewer strokes, deaths and cardiovascular complications. Before this landmark study, high blood pressure was not recognized as a disease requiring treatment. There were even physicians who felt that high blood pressure was a phenomenon of aging and that hi...
Source: Healthy Living - The Huffington Post - September 22, 2015 Category: Consumer Health News Source Type: news

Everolimus-Stent PCI Effective in Most CKD Patients: AnalysisEverolimus-Stent PCI Effective in Most CKD Patients: Analysis
PCI wth modern stents seemed an effective alternative to CABG, which guidelines favor in patients with chronic kidney disease; the analysis also provides hints about subgroups that might do better with surgery. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 18, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

High dietary sodium, potassium may worsen chronic kidney disease
High dietary intake of sodium and potassium may speed the progression of kidney disease, according to a new study. Researchers found that high urinary excretion levels of both sodium and potassium were linked with faster progression of chronic kidney disease. Additionally, they noted that patients with chronic kidney disease tend to consume sodium above the recommended daily limit. An estimated 26 million people in the United States have chronic kidney disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 18, 2015 Category: Science Source Type: news

A High Salt and Potassium Diet May Accelerate Chronic Kidney Disease
Study participants had far more sodium than the recommended daily limit (Source: WebMD Health)
Source: WebMD Health - September 17, 2015 Category: Consumer Health News Source Type: news

A High Salt and Potassium Diet May Accelerate Chronic Kidney Disease
Study participants had far more sodium than the recommended daily limit Source: HealthDay Related MedlinePlus Pages: Chronic Kidney Disease, Potassium, Sodium (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 17, 2015 Category: Consumer Health News Source Type: news

The New Old Age: Chronic Kidney Disease Can Be Dubious Diagnosis
The condition is so common in older patients that some experts wonder whether it should be considered a disease. (Source: NYT Health)
Source: NYT Health - September 14, 2015 Category: Consumer Health News Authors: PAULA SPAN Tags: Dialysis Elderly Medicine and Health Kidneys Source Type: news

​Amgen files for FDA approval for drug to treat dialysis patients
Amgen Inc. said it has filed for approval to sell its drug to treat patients with chronic kidney disease on dialysis. Thousand Oaks-based Amgen(Nasdaq: AMGN) said it submitted a new drug application to the U.S. Food and Drug Administration for etelcalcetide, formerly AMG 416, for the treatment of secondary hyperparathyroidism, a condition that can cause fragile bones, bone pain and organ damage. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 26, 2015 Category: American Health Source Type: news

7 Tips for Traveling With a Parent on Dialysis
Today, kidney disease is the 9th leading cause of death in the United States. About 23 million Americans currently suffer from chronic kidney disease, and nearly 400,000 of them need dialysis. Most use hemodialysis, a procedure that can be done either at home or in a specialized facility and requires the patient to be connected to a large machine for hours at a time, several days a week. If your parent uses hemodialysis, you may think that such a treatment regimen means that his or her traveling days are done. But that doesn't have to be the case! With a little bit of planning, it's quite possible for your parent to travel...
Source: Healthy Living - The Huffington Post - August 14, 2015 Category: Consumer Health News Source Type: news

Proteon begins second Phase III trial of vonapanitase for CKD
Proteon Therapeutics has enrolled first patient in the second Phase III clinical study of its investigational product candidate vonapanitase (formerly PRT-201) for chronic kidney disease (CKD). (Source: Drug Development Technology)
Source: Drug Development Technology - August 12, 2015 Category: Pharmaceuticals Source Type: news

Jade Fowles who donated kidney to save critically ill partner's life marries him
Jade Crawford, 28, married Ben Fowles, 30, from Birmingham, 15 months after she was found to be a perfect match as a donor when he was diagnosed with chronic kidney disease. (Source: the Mail online | Health)
Source: the Mail online | Health - August 12, 2015 Category: Consumer Health News Source Type: news

Woman who donated a kidney to save her critically ill partner's life marries him in fairy tale wedding
Jade Crawford, 28, married Ben Fowles, 30, from Birmingham, 15 months after she was found to be a perfect match as a donor when he was diagnosed with chronic kidney disease. (Source: the Mail online | Health)
Source: the Mail online | Health - August 11, 2015 Category: Consumer Health News Source Type: news

Pair of deals moves Peninsula biotech closer to drug starting line
Relypsa Inc. inked a key drug-selling deal as it moved closer to regulatory approval of a new drug aimed at helping chronic kidney disease patients clear potentially fatal levels of potassium. The fast-growing Redwood City company (NASDAQ: RLYP) said Monday that it would pay Sanofi up to $10 million a year during the launch patiromer in the United States, if the Food and Drug Administration approves the drug in October. The company also said it signed a deal with Vifor Fresenius Medical Care Renal… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - August 11, 2015 Category: Hospital Management Authors: Ron Leuty Source Type: news

Pair of deals moves Peninsula biotech closer to drug starting line
Relypsa Inc. inked a key drug-selling deal as it moved closer to regulatory approval of a new drug aimed at helping chronic kidney disease patients clear potentially fatal levels of potassium. The fast-growing Redwood City company (NASDAQ: RLYP) said Monday that it would pay Sanofi up to $10 million a year during the launch patiromer in the United States, if the Food and Drug Administration approves the drug in October. The company also said it signed a deal with Vifor Fresenius Medical Care Renal… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 11, 2015 Category: Biotechnology Authors: Ron Leuty Source Type: news

Kidney Problems Linked to Brain Disorders
Reduced blood flow likely to blame, researcher suggests Source: HealthDay Related MedlinePlus Pages: Brain Diseases, Chronic Kidney Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 6, 2015 Category: Consumer Health News Source Type: news

Socio-economic Status and Chronic Kidney Disease PrevalenceSocio-economic Status and Chronic Kidney Disease Prevalence
What factors account for variation in chronic kidney disease prevalence in primary care? Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2015 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Byproduct of intestinal bacteria may jeopardize heart health in patients with kidney disease
Blood levels of TMAO, a byproduct generated from intestinal bacterial as they metabolize dietary nutrients, progressively increase with advancing severity of kidney disease. TMAO levels are dramatically reduced when kidney function is restored following kidney transplantation, researchers say, noting that high TMAO levels are linked with an increased risk of atherosclerosis and premature death in patients with chronic kidney disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 30, 2015 Category: Science Source Type: news

Lessons from a Pioneer ACO
(MedPage Today) -- Atrius Health improves chronic kidney disease care through enhanced Medicare data (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - July 30, 2015 Category: Geriatrics Source Type: news

CHMP Says Yes to Ferric Citrate for CKDCHMP Says Yes to Ferric Citrate for CKD
The EMA committee recommended approval of ferric citrate (Fexeric) for hyperphosphatemia in adults with chronic kidney disease on or off dialysis. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 29, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

Tailored mobile health technologies may help patients take their medications appropriately
There was only a 5 percent error rate when patients with chronic kidney disease used mobile health technologies designed to help them use medications appropriately. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 28, 2015 Category: Science Source Type: news

Opko Health stock gains on FDA announcement
Opko Health shares traded up 1.5 percent on Tuesday afternoon after the FDA decided to initiate a review of the company’s Rayaldee drug candidate. The Miami-based biotech and pharmaceutical company (NYSE: OPK), headed by billionaire Chairman and CEO Dr. Phillip Frost, is seeking approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D (CKD) deficiency. Opko submitted an application for the drug based… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 28, 2015 Category: Biotechnology Authors: Brian Bandell Source Type: news

Opko Health stock gains on FDA announcement
Opko Health shares traded up 1.5 percent on Tuesday afternoon after the FDA decided to initiate a review of the company’s Rayaldee drug candidate. The Miami-based biotech and pharmaceutical company (NYSE: OPK), headed by billionaire Chairman and CEO Dr. Phillip Frost, is seeking approval for Rayaldee for the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D (CKD) deficiency. Opko submitted an application for the drug based… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - July 28, 2015 Category: Hospital Management Authors: Brian Bandell Source Type: news

Op-Ed: Let's Connect the Chronic Kidney Disease Dots
(MedPage Today) -- Incredibly, most ESRD patients are barred from Medicare Advantage. That must end. (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - July 27, 2015 Category: Surgery Source Type: news

Potential new targets for treating kidney disease
Proteins in the Wnt signaling pathway help drive kidney scarring that can lead to chronic kidney disease, researchers report. When investigators examined the complex process of scarring, or fibrosis, in failing kidneys, they discovered that proteins in the Wnt signaling pathway play a critical role in the crosstalk between cells as scarring occurs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 23, 2015 Category: Science Source Type: news

NSAIDS may increase kidney risks with high blood pressure
(Reuters Health) - People with high blood pressure who regularly take common painkillers known as non-steroidal anti-inflammatory drugs (NSAIDs) may increase their risk of developing chronic kidney disease, a study from Taiwan suggests. (Source: Reuters: Health)
Source: Reuters: Health - July 23, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

iPSCs show promise for kidney treatment
Renal progenitor cells derived from human iPS cells were shown to have therapeutic effects when transplanted into acute kidney injury model mice. The transplants resulted in a significant reduction of fibrosis, suggesting that they may have preventative measures against chronic kidney disease. The positive effects were attributed to the secretion of renoprotective factors. Using this iPS cell model to identify these factors could lead to new drug candidates. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 21, 2015 Category: Science Source Type: news

iPSCs show promise for kidney treatment
(Center for iPS Cell Research and Application - Kyoto University) Renal progenitor cells derived from human iPS cells were shown to have therapeutic effects when transplanted into acute kidney injury model mice. The transplants resulted in a significant reduction of fibrosis, suggesting that they may have preventative measures against chronic kidney disease. The positive effects were attributed to the secretion of renoprotective factors. Using this iPS cell model to identify these factors could lead to new drug candidates. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 21, 2015 Category: Biology Source Type: news

Pregnancy in Advanced CKD and End-stage Renal DiseasePregnancy in Advanced CKD and End-stage Renal Disease
How should clinicians manage pregnancy in women with advanced chronic kidney disease and end-stage renal disease, and what are the outcomes? Current Opinion in Nephrology and Hypertension (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - July 12, 2015 Category: Urology & Nephrology Tags: Nephrology Journal Article Source Type: news

Electrocardiogram screening may help predict kidney disease patients' risk of dying from heart disease
Certain electrocardiogram measures helped investigators identify a subgroup of individuals with chronic kidney disease who had substantially elevated risks of dying from heart disease, a new article reports. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 9, 2015 Category: Science Source Type: news

New strategies for combatting chronic kidney disease, other long-term conditions
New strategies for using electronic health records (EHRs) to treat patients with chronic kidney disease have been outlined by investigators. Their recommendations may help clinicians and hospitals better manage individual patients with chronic conditions and identify groups of patients most likely to benefit from different treatment strategies. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 25, 2015 Category: Science Source Type: news

First ESC recommendations for arrhythmias, chronic kidney disease published
Significant interactions occur between the heart and kidney, and even mild kidney disease is associated with an increased risk of cardiovascular disease. Sudden cardiac death is the most common cause of death in dialysis patients including children, accounting for 50% of cardiac deaths and 25% of all deaths. Now experts have released recommendations for patients with cardiac arrhythmias and chronic kidney disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 24, 2015 Category: Science Source Type: news

First ESC recommendations for arrhythmias and chronic kidney disease published
(European Society of Cardiology) The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease are presented today1 at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.2 (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 24, 2015 Category: Global & Universal Source Type: news